The European Commission announced a new 50mg Enbrel® (etanercept) once weekly dosage regimen as an alternative to the currently approved 25mg Enbrel® twice weekly regimen for the treatment of patients with moderate-to-severe plaque psoriasis. Based on the outcome of the extensive European 318 study in adult patients with moderate-to-severe plaque psoriasis, the European Commission issued the marketing authorisation for the European Union for a once weekly 50mg Enbrel® dosing.

This post is an original post by ScienceDaily: Skin Care News